The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, said compound having the structure: Formula (I). ##STR00001##

The present invention relates to a method for the synthesis of cyclic depsipeptides, in particular emodepside, from the open form.

The application relates to phenyl- or naphthylsulfonamide derivatives of the structural formula (I). The compounds are described as inhibitors of USP30 (ubiquitin specific peptidase 30) useful for the treatment of conditions involving mitochondrial defects including neurodegenerative diseases such as Alzheimer's and Parkinson's or a neoplastic disease such as leukemia. ##STR00001##

The application relates to phenyl- or naphthylsulfonamide derivatives of the structural formula (I). The compounds are described as inhibitors of USP30 (ubiquitin specific peptidase 30) useful for the treatment of conditions involving mitochondrial defects including neurodegenerative diseases such as Alzheimer's and Parkinson's or a neoplastic disease such as leukemia. ##STR00001##

Provide are a liquid crystal compound represented by formula I, and a liquid crystal mixture comprising the compound ##STR00001## A lateral trifluoromethyl-containing liquid crystal compound having the structural characteristics of Formula I not only has a negative dielectric anisotropy (Δε), an appropriate optical anisotropy (Δn), a higher clearing point (CP), a prominent low-temperature miscibility with other liquid crystals, and a low rotary viscosity (γ1), but also has a good stability to UV and high temperatures, particularly, a negative dielectric anisotropy. Same can be applied to the formulation of liquid crystal compositions of positive and negative types, and it is particularly prominent that same has the advantages of a good solubility at low temperatures and a high transmittance.

Provide are a liquid crystal compound represented by formula I, and a liquid crystal mixture comprising the compound ##STR00001## A lateral trifluoromethyl-containing liquid crystal compound having the structural characteristics of Formula I not only has a negative dielectric anisotropy (Δε), an appropriate optical anisotropy (Δn), a higher clearing point (CP), a prominent low-temperature miscibility with other liquid crystals, and a low rotary viscosity (γ1), but also has a good stability to UV and high temperatures, particularly, a negative dielectric anisotropy. Same can be applied to the formulation of liquid crystal compositions of positive and negative types, and it is particularly prominent that same has the advantages of a good solubility at low temperatures and a high transmittance.

Disclosed are a series of compounds or their tautomers having a general structure represented by Formula Ia, Ib, IIa, IIb, or IIc and pharmaceutically acceptable salts thereof. The present disclosure also relates to pharmaceutical compositions comprising said compounds or tautomers. The present disclosure further relates to a method of treating a disease or condition associated with iron dysregulation or dysfunctional iron homeostasis comprising administering to a subject in need thereof a therapeutically effective amount of Formula Ia, Ib, IIa, IIb, or IIc compounds or tautomers.

Disclosed are a series of compounds or their tautomers having a general structure represented by Formula Ia, Ib, IIa, IIb, or IIc and pharmaceutically acceptable salts thereof. The present disclosure also relates to pharmaceutical compositions comprising said compounds or tautomers. The present disclosure further relates to a method of treating a disease or condition associated with iron dysregulation or dysfunctional iron homeostasis comprising administering to a subject in need thereof a therapeutically effective amount of Formula Ia, Ib, IIa, IIb, or IIc compounds or tautomers.

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.